Stockscreener 앱 받기
3.08
11.59%
0.32
시간 외 거래:
2.98
-0.10
-3.25%
Editas Medicine Inc 주식(EDIT)의 최신 뉴스
Editas Medicine (NASDAQ: EDIT) prices equity deal, extends cash runway to 2H 2028 - Stock Titan
EDIT: Financing Efforts Advance with Recent Offering - GuruFocus
Editas Medicine (EDIT) Shares Drop Following Stock Offering Anno - GuruFocus
Editas Medicine stock dips on proposed equity offering - MSN
Editas Medicine prices $125M stock offering with warrants By Investing.com - Investing.com Australia
Editas reports preclinical data for gene editing treatment - Investing.com UK
Editas Medicine prices $125M stock offering with warrants - Investing.com
Editas Medicine stock tumbles on stock offering announcement By Investing.com - Investing.com Nigeria
Editas offering links warrant window to cholesterol trial results - Stock Titan
Editas Medicine stock tumbles on stock offering announcement - Investing.com
Editas Medicine (NASDAQ: EDIT) halts sales under TD Cowen ATM prospectus - Stock Titan
Editas Medicine Proposes Public Stock Offering; Shares Fall Pre-Bell - Moomoo
Editas Medicine (EDIT) Showcases Promising Preclinical Findings for EDIT-401 - GuruFocus
Editas Medicine (EDIT) Initiates Public Offering of Common Stock - GuruFocus
Editas Medicine launches public offering of stock and warrants - Investing.com
Editas reports preclinical data for gene editing treatment By Investing.com - Investing.com Australia
Editas Medicine (NASDAQ: EDIT) offers common shares, pre-funded warrants and detachable warrants - Stock Titan
EDIT-401 gene-editing data and trial path at Editas Medicine (NASDAQ: EDIT) - Stock Titan
Editas Medicine Announces Proposed Public Offering - Caledonian Record
Gene-editing firm Editas moves to sell new shares and warrants - Stock Titan
Editas Medicine Presents EDIT-401 Preclinical Data Showing ~90% Cuts in LDL-C, Lp(a), and ApoB; CTN Planned Mid-2026 - TradingView
Editas Medicine Announces Promising Preclinical Results for EDIT-401, Showcasing Significant Reductions in LDL-C, Lp(a), and ApoB - Quiver Quantitative
One-shot gene edit slashes multiple cholesterol drivers in animal tests - Stock Titan
Editas Medicine stock (US28106W1036): Recent clinical updates keep investors focused - AD HOC NEWS
Editas Medicine Unveils New Data on EDIT-401 for Hyperlipidemia - Intellectia AI
EDIT's Q1 loss narrower than expected, pipeline in focus - MSN
Analyst Forecasts Just Became More Bearish On Editas Medicine, Inc. (NASDAQ:EDIT) - Moomoo
JonesTrading Maintains Editas Medicine(EDIT.US) With Buy Rating, Raises Target Price to $8 - Moomoo
EDIT Stock Price, Quote & Chart | EDITAS MEDICINE INC (NASDAQ:EDIT) - ChartMill
Editas Medicine Reports Durable ≥90% LDL-C Reduction With Single Dose of EDIT-401 in Preclinical Hyperlipidemia Data at ASGCT 2026 - Minichart
Editas Medicine stock (US28106W1036): EDIT-401 shows 90% LDL reduction in preclinical study - AD HOC NEWS
Editas Medicine (EDIT) Advances Gene Editing Candidate for Hyper - GuruFocus
Editas Medicine presents preclinical data on EDIT-401 therapy By Investing.com - Investing.com Australia
Editas Medicine presents preclinical data on EDIT-401 therapy - Investing.com UK
Editas Showcases Promising EDIT-401 Hyperlipidemia Preclinical Data - TipRanks
EDIT-401 preclinical data show ≥90% LDL-C drop in primates (EDIT) - Stock Titan
Editas Reports ≥90% Mean LDL-C Reduction with Single EDIT-401 Dose in NHPs; Durable ~6 Months - TradingView
Editas Medicine Reports New Preclinical Data Demonstrating - GlobeNewswire
Gene editing test from Editas cuts LDL cholesterol 90% in monkeys - Stock Titan
Editas Medicine presents new in vivo gene editing data on EDIT-401 at TIDES USA 2026 Meeting - Traders Union
Editas Medicine unveils cardiovascular research at ASGCT and TIDES USA events - Traders Union
Some Analysts Just Cut Their Editas Medicine, Inc. (NASDAQ:EDIT) Estimates - Yahoo Finance
Editas Medicine (NASDAQ:EDIT) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Editas Medicine Inc. (EDIT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Analysts Offer Insights on Healthcare Companies: Brookdale Senior Living (BKD), Tempus AI, Inc. Class A (TEM) and Editas Medicine (EDIT) - The Globe and Mail
Earnings Update: Editas Medicine, Inc. (NASDAQ:EDIT) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
BofA Securities Maintains Editas Medicine(EDIT.US) With Sell Rating - Moomoo
RBC Capital Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $4 - Moomoo
EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus - The Globe and Mail
Editas Medicine posts first quarter 2026 results and provides business update - Traders Union
A Quick Look at Today's Ratings for Editas Medicine(EDIT.US), With a Forecast Between $3 to $4 - Moomoo
0.98%
0.12%
자본화:
|
볼륨(24시간):